955095-47-3
Chemical Structure
Azeloprazole sodium
- CAS No.: 955095-47-3
- Formula:C22H26N3NaO4S
- Molecular Weight:451.51
IUPAC Name: sodium (R)-2-(((4-((2,2-dimethyl-1,3-dioxan-5-yl)methoxy)-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide
InChIKey: HXDOUUHARCBYLF-VNUFCWELSA-N
SMILES: O=[S@@](C1=NC2=CC=CC=C2[N-]1)CC3=NC=C(C)C(OCC4COC(C)(C)OC4)=C3C.[Na+]
Biological Activity: Azeloprazole sodium is an orally active proton pump inhibitor. Azeloprazole sodium irreversibly binds to and blocks the proton pump (H+/K+-ATPase) on parietal cells, thereby inhibiting gastric acid secretion. Azeloprazole sodium is primarily metabolized by the CYP3A4 enzyme, and its pharmacokinetics and acid-suppressive effects are independent of CYP2C19 activity. Azeloprazole sodium can be used for research on acid-related diseases such as reflux esophagitis and gastroesophageal reflux disease[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Azeloprazole sodium | Azeloprazole sodium is an orally active proton pump inhibitor. Azeloprazole sodium irreversibly binds to and blocks the proton pump (H+/K+-ATPase) on parietal cells, thereby inhibiting gastric acid secretion. Azeloprazole sodium is primarily metabolized by the CYP3A4 enzyme, and its pharmacokinetics and acid-suppressive effects are independent of CYP2C19 activity. Azeloprazole sodium can be used for research on acid-related diseases such as reflux esophagitis and gastroesophageal reflux disease. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Srebro J, et al. Formulation of Dosage Forms with Proton Pump Inhibitors: State of the Art, Challenges and Future Perspectives. Pharmaceutics. 2022 Sep 25;14(10):2043.
- [2]. Kinoshita Y, et al. Efficacy and Safety Profile of Z-215 (Azeloprazole Sodium), a Proton Pump Inhibitor, Compared with Rabeprazole Sodium in Patients with Reflux Esophagitis: A Phase II, Multicenter, Randomized, Double-Blind, Comparative Study. Current therapeutic research, clinical and experimental. 2018;88:26-34.
- [3]. Simadibrata DM, et al. Experimental drugs for erosive esophagitis: what is in the clinical development pipeline?. Expert opinion on investigational drugs. 2024 Oct;33(10):1009-1018.
- [4]. Hunt RH, et al. Potent Acid Suppression with PPIs and P-CABs: What's New?. Current treatment options in gastroenterology. 2018 Dec;16(4):570-590.
